Business
GeoVax Expands Gedeptin(R) Development to Additional Solid Tumor Indications
Initiative Builds on Checkpoint Inhibitor Momentum and Landmark KEYNOTE-689 Results ATLANTA, GA - September 24, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies aga...
About this update from Geovax Labs, Inc.
[{"type":"image","caption":"","headline":"GeoVax Highlights 2026 as a Pivotal Year for Progress","size":{"original":{"width":140,"height":140,"url":"https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CK3y_RQaAtNDQGf8lPQXOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc","width":140,"height":140}}},{"type":"text","content":"Initiative Builds on Checkpoint Inhibitor Momentum and Landmark KEYNOTE-689 Results","length":83,"tagName":"p"},{"type":"text","content":"ATLANTA, GA - September 24, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against cancers and infectious diseases, today announced the expansion of its oncology development strategy to include assessments of additional solid tumor targets for Gedeptin(R), its gene-directed enzyme prodrug therapy (GDEPT).","length":394,"tagName":"p"},{"type":"text","content":"Working closely with its oncology advisory team including the Winship Cancer Institute of Emory University, GeoVax is evaluating the combination of Gedeptin with immune checkpoint inhibitors in preclinical models of several solid tumor types. These models are designed to validate Gedeptin's mechanism - localized intratumoral cytotoxicity that also primes systemic immune responses - in tumor settings beyond head and neck cancer such as triple negative breast cancer and cutaneous malignancies.","length":500,"tagName":"p"},{"type":"text","content":"Phase 2 Clinical Trial","length":22,"tagName":"p"},{"type":"text","content":"GeoVax previously announced updated plans for a Phase 2 clinical trial, AdPNP-203, which will evaluate the addition of intra-tumoral Gedeptin(R) and intravenous fludarabine to recently approved neoadjuvant pembrolizumab as first-line treatment of patients with head and neck squamous cell carcinoma eligible for curative surgery. The trial is designed to assess major pathological response (MPR) and associated immunologic and biomarker outcomes following two pre-surgical cycles of therapy, as well as event-free survival over a one-year period. Gedeptin's tumor-targeting, immune-sensitizing mechanism may help overcome the limitations of checkpoint monotherapy by enhancing immune ...